InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
10
T+90 hit rate
0%
T+90 mean return
-26.1%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Meisner Derek M, Chief Executive Officer. Director active across 2 companies, notably X4 Pharmaceuticals, Inc. Cumulatively, 19 reports have been recorded. Split: 0 buy · 10 sells. Total volume traded: €132k. Activity tracked since 15 June 2021. The latest transaction was filed on 6 March 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations19 total
2,090 shares@ US$1.850.0020% mcap5.3% of flowCommon StockSEC:0001628280-26-016645:0
2,090 shares@ US$3.260.0035% mcap9.3% of flowCommon StockSEC:0001628280-26-016645:1
3,418 shares@ US$1.598.3% of flowCommon StockSEC:0001576885-25-000033:0
11,122 shares@ US$1.843731.7% of flowCommon StockSEC:0001576885-25-000015:0
66,800 shares0Common StockSEC:0001576885-25-000015:1
8,933 shares@ US$3.475745.4% of flowCommon StockSEC:0001576885-24-000027:0
91,000 shares0Common StockSEC:0001576885-24-000012:0
26,800 shares0Common StockSEC:0001209191-23-003735:0
8,334 sharesCommon StockSEC:0001628280-22-023326:0
4,166 sharesCommon StockSEC:0001628280-22-018042:0
4,166 sharesCommon StockSEC:0001628280-22-017433:0
105,000 shares0Common StockSEC:0001628280-22-004493:0
15,909 sharesCommon StockSEC:0001628280-22-002509:0
8,332 shares@ US$5.1050.0% of flowCommon StockSEC:0001628280-21-017332
8,332 shares@ US$5.100.0098% mcap50.0% of flowCommon StockSEC:0001628280-21-017332:0
12,500 shares0Common StockSEC:0001628280-21-012932
12,500 shares0Common StockSEC:0001628280-21-012932:0
12,500 shares0Common StockSEC:0001628280-21-012478
12,500 shares0Common StockSEC:0001628280-21-012478:0
19 of 19 declarations
About Meisner Derek M
Derek M. Meisner is the General Counsel and Chief Legal Officer of X4 Pharmaceuticals, Inc. In this role, he is responsible for the legal and compliance matters of the company, which focuses on developing innovative treatments. Derek plays a key role in managing legal risks and protecting the interests of the company.
